Skip to main content
Fig. 7 | European Journal of Medical Research

Fig. 7

From: CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer

Fig. 7

CDK6 inhibitors decreased the expression of CDK6 and suppressed cell proliferation in both PCa and EnzR PCa cells. A The mRNA expression of CDK6 after LNCaP cells and EnzR LNCaP cells treated by CDK6 inhibitors (apigenin, chrysin, fisetin). B The expression of CDK6 in mRNA level after C4-2 cells and EnzR C4-2 cells treated by CDK6 inhibitors. C CDK6 inhibitors can suppress CDK6 protein expression in LNCaP cells and EnzR LNCaP cells. D The CDK6 protein level decreased after CDK6 inhibitors treated C4-2 cells and EnzR C4-2 cells. E The cell proliferation was decreased after ordinary LNCaP and EnzR LNCaP treated by CDK6 inhibitors by CCK-8. F Normal C4-2 and EnzR C4-2 cells proliferation ability was decreased after CDK6 inhibitors used. *represents P < 0.05, **represents P < 0.01, ***represents P < 0.001. The data were shown in mean ± SD. The qRT-PCR and western blot using β-tubulin as inner control

Back to article page